Form 4: Royalty Pharma Director Acquires Shares in Lieu of Quarterly Retainer

Henry A. Fernandez, a director of Royalty Pharma plc, acquired 1,141 Class A Ordinary Shares on March 31, 2025, in lieu of a quarterly retainer payment.

Summary

• On March 31, 2025, Henry A. Fernandez, a director of Royalty Pharma plc, acquired 1,141 Class A Ordinary Shares.
• The shares were acquired under the Issuer's 2020 Independent Director Equity Incentive Plan.
• The acquisition was in lieu of a quarterly retainer payment of $37,500, with the shares acquired at a price of $32.8658 each.
• Following the transaction, Mr. Fernandez directly owns 56,646 Class A Ordinary Shares.
• Mr. Fernandez also indirectly owns 58,200 Class A Ordinary Shares through the Fernandez 2007 Children's Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. A director acquiring shares is generally a good sign, indicating confidence in the company's future. The acquisition being in lieu of cash is also a positive for the company's cash flow.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• The use of equity in lieu of cash preserves company cash flow.

Industry Context

Director share acquisitions are common and often viewed positively by investors as they align management's interests with those of shareholders. Using equity for compensation is a common practice in the pharmaceutical industry.

Comparison to Industry Standards

• Comparing Royalty Pharma's director compensation structure to companies like AbbVie, Johnson & Johnson, and Pfizer, it's common to see a mix of cash and equity-based compensation.
• The specific amount and type of equity grants can vary widely based on company size, performance, and individual director roles.
• Director compensation packages are typically benchmarked against peer companies to ensure competitiveness.

Stakeholder Impact

• Shareholders may view the director's share acquisition positively.
• The company benefits from preserving cash by issuing shares instead of making a cash payment.

Key Dates

Keywords

Royalty Pharma, Director, Share Acquisition, Form 4, RPRX, Equity Incentive Plan, Henry A. Fernandez